We have a portfolio of potent enzyme mimetics which inhibit inflammatory and oxidative injury, with UP1007 as our lead compound.
|Implications for human therapy|
|Carboxyfullerenes as neuroprotective agents (1997)||
|A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties (2004)||
|A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice (2006)||
|Ketamine-Induced Loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase (2007)||
|SOD Activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study (2008)||
|Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates (2014)||
|Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid [C3] in Mice and Primates (2018)||
|Reduction of Leukocyte Microvascular Adherence and Preservation of Blood-Brain Barrier Function by Superoxide-Lowering Therapies in a Piglet Model of Neonatal Asphyxia (2019)||
‘UP-1007’ is a derivatized fullerene (60 carbon ball). Unify’s unique product can be taken by mouth and spreads throughout the body – including the brain. It is envisaged that this product will be used to target major diseases which currently have clinically unmet needs.
Fig. 1 Brain PET imaging of Parkinsonian monkeys: 80% protection by UP1007, none by placebo
Modified from Dugan et, Ann Neuroll., 2014. Unify Pharmaceuticals has obtained permission for the use of these figures from the Annals of Neurology.
FIGURE 2: Dynamic functional assessment of Parkinson symptoms. Animals rated on an 18-point scale that assesses severity of symptoms. *UP1007 significantly better than placebo.
FIGURE 3: Parkinson motor scores in primates at the end of the study. Data are the mean scores after 8 weeks of drug treatment.
A pre-clinical study in 2014 showed the marked efficacy of C3 on primates afflicted with Parkinson’s (PD). This test was particularly significant for the nature of the subjects; most trials in this area are conducted on animals such as mice which are not biologically similar enough to humans to fully prove efficacy against PD. Statistically significant differences between UP1007 and Placebo groups began to appear after 30 days. No toxicity from UP1007 was observed (Hardt et al., 2018)
Unify Pharmaceuticals holds intellectual property in the US, protecting its proprietary research.
|Patent Number||Description||Date Granted|
|7,145,032; 7,511,075||Therapeutic malonic acid/acetic acid C.sub.60 trl-adducts of buckminsterfullerene and methods related thereto||December 5, 2006; March 3, 2009|
|9,035,057||Dihydroethidine analogues and uses thereof||May 19, 2015|
|9,550,827||Methods for ameliorating and preventing central nervous system inflammation||January 24, 2017|
|10644_058PV1_2017_11_15||Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative diseases.||Pending: Submitted November, 2019|